Annual report [Section 13 and 15(d), not S-K Item 405]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

    

Year Ended December 31, 

($ in thousands)

    

2024

    

2023

Qbrexza®

​

$

25,114

​

$

25,410

Accutane®

​

​

19,407

​

​

20,168

Amzeeq®

​

​

5,009

​

​

6,201

Zilxi®

​

 

1,643

​

 

1,962

Other / legacy

​

​

3,961

​

​

5,921

Total product revenues

​

$

55,134

​

$

59,662

Schedule of other revenue

​

​

​

​

​

​

​

​

​

    

Year Ended December 31,

($in thousands)

​

2024

    

2023

Milestone payment from Cutia

​

$

1,000

​

$

—

Non-refundable upfront payment from Maruho

 

​

—

​

​

19,000

Royalties on sales of Rapifort® Wipes 2.5%

​

​

—

​

​

519

Total other revenue

​

$

1,000

​

$

19,519